Form 4: Edgewell CEO's Stock Transactions & Vesting Update

Edgewell Personal Care CEO Rod R. Little reported the vesting of performance stock equivalents, a tax-related share disposition, and a new grant of restricted stock equivalents.

Summary

• Rod R. Little, Chief Executive Officer and Director of Edgewell Personal Care Co (EPC), reported several stock transactions.
• On November 13, 2025, 58,612 Performance Stock Equivalents (PSEs) vested and converted into shares of EPC common stock. The original award was 166,038 shares, meaning 107,426 shares were cancelled as performance criteria were not met.
• Following the vesting, 27,167 shares of common stock were disposed of at a price of $18.39 per share to cover tax liabilities associated with the vesting.
• After these transactions, Mr. Little's direct beneficial ownership of common stock decreased from 392,985 shares to 365,818 shares.
• On November 14, 2025, Mr. Little was granted 103,420 Restricted Stock Equivalents (RSEs).
• These RSEs will vest in three equal installments (one-third each) on November 14, 2026, November 14, 2027, and November 14, 2028, contingent on his continued employment, with potential accelerated vesting upon death, disability, change in control, or certain termination events.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a significant portion of performance shares were cancelled, indicating underperformance against specific metrics, the vesting of a substantial number of shares and the grant of a new, large restricted stock award provide ongoing executive incentive and retention, which is generally viewed favorably.

Positives

• The vesting of 58,612 Performance Stock Equivalents demonstrates a payout from a previous incentive plan.
• A new grant of 103,420 Restricted Stock Equivalents provides ongoing incentive and aligns management interests with long-term shareholder value.

Negatives

• A significant portion of the original Performance Stock Equivalents award (107,426 shares out of 166,038) was cancelled, indicating that performance criteria were not fully met.
• 27,167 shares were sold to cover tax liabilities, resulting in a reduction of direct common stock ownership.

Risks

• The vesting of the newly granted 103,420 Restricted Stock Equivalents is contingent on the reporting person's continued employment, posing a risk of forfeiture if employment ceases before vesting dates.

Future Outlook

The CEO's future compensation includes 103,420 Restricted Stock Equivalents that are scheduled to vest in three annual installments starting November 14, 2026, contingent on continued employment and other specific events.

Management Comments

• Rod R. Little acquired 58,612 shares of common stock through the vesting of performance stock equivalents.
• Mr. Little disposed of 27,167 shares of common stock to satisfy tax withholding obligations related to the vesting.
• Mr. Little was granted 103,420 Restricted Stock Equivalents, which will vest over three years subject to employment conditions.

Industry Context

This filing details routine executive compensation activities, specifically the vesting of performance-based awards and the grant of new restricted stock. Such transactions are common across publicly traded companies as a mechanism for executive incentive and retention, aligning management's long-term interests with shareholder value. It does not directly reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The vesting and grant of equity awards impact executive compensation structure and may lead to minor dilution over time, but also aim to align management's interests with long-term shareholder value.
• Employees: The CEO's compensation structure serves as a benchmark and incentive model within the company's broader compensation framework.

Next Steps

• One-third of the 103,420 Restricted Stock Equivalents are scheduled to vest on November 14, 2026.
• One-third of the 103,420 Restricted Stock Equivalents are scheduled to vest on November 14, 2027.
• The final one-third of the 103,420 Restricted Stock Equivalents are scheduled to vest on November 14, 2028.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of performance-based awards and the grant of new restricted stock. It does not contain new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard disclosure of insider transactions.

Keywords

Edgewell Personal Care, EPC, Form 4, Insider Transaction, Executive Compensation, Stock Vesting, Restricted Stock Equivalents, Performance Stock Equivalents, Rod R. Little, Equity Compensation